

**Master of Medicine in Emergency Medicine
Faculty of Health Sciences
University of the Witwatersrand**

Co-existing Diabetic Ketoacidosis and COVID-19

***A profile of patients presenting to a regional Emergency
Department during the COVID-19 pandemic in Johannesburg,
South Africa***

Author:

Dr Hanlie Dreyer

Student number: 552715

Supervisor:

Dr Pravani Moodley

Institution:

Department of Emergency Medicine
University of the Witwatersrand
Johannesburg, South Africa

Date of Submission:

May 2025

Title: Co-existing Diabetic Ketoacidosis and COVID-19 – a profile of patients presenting to a regional Emergency Department during the COVID-19 pandemic in Johannesburg, South Africa

Background: This study aimed to describe the clinical features and severity of illness in patients diagnosed with both SARS-CoV-2 (COVID-19) and Diabetic Ketoacidosis (DKA) at a South African regional hospital.

Methods: This was a single centre, retrospective, observational study in a regional hospital in Johannesburg, South Africa. Files from patients who presented to the Emergency Department (ED) between the period 1 April 2020 to 31 August 2021 and diagnosed with DKA were identified from registers. Patients who tested both positive and negative for COVID-19 were included in the study.

Results: Of the 104 DKA patients identified, 35 (33.65%) tested positive for COVID-19. Among the COVID-19 positive group, two required ICU admission and two were admitted to the High Care Unit (HCU). Medical interventions included high-flow nasal cannula (1 patient), intubation (2 patients) and inotropic support (1 patient). Outcomes included one death (2.86%), one patient declining treatment and one transfer. There was a statistically significant association with increased age in the COVID-19 positive cohort ($p=0.02$) and positive association observed between the COVID-19 positive cohort and DM Type 2 ($p=0.03$).

Conclusion: This retrospective study demonstrated that patients with COVID-19 and DKA had a lower mortality rate than previously described. In patients with both COVID-19 and DKA, a significant association with advanced age and Type 2 Diabetes Mellitus was noted.
Keywords: diabetic ketoacidosis; COVID-19

Contribution:

There is a paucity of data on co-existing DKA and COVID-19's burden of disease on the health care system. This research noted a significant lower mortality rate in patients with COVID-19 and DKA than previously published.

Keywords: diabetic ketoacidosis; COVID-19

Title: Co-existing Diabetic Ketoacidosis and COVID-19 – a profile of patients presenting to a regional Emergency Department during the COVID-19 pandemic in Johannesburg, South Africa.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) was first described in Wuhan, China in December 2019, and has since been declared a global pandemic. South Africa declared a state of disaster in March 2020. Globally more than 770 million people have been infected with SARS COV-2 and more than 7 million COVID-19 related deaths have been reported [1,2]. Patients with comorbidities such as hypertension, diabetes and cardiovascular disease are predisposed to more severe forms of COVID-19 as well as a higher mortality rate [3,4].

Multiple case studies and expert recommendations have been published exploring the bidirectional relationship between COVID-19, hyperglycaemia and diabetes mellitus [3,5,6,7]. Angiotensin converting enzyme 2 acts as an entry point for SARS-CoV-2 and certain diabetogenic effects of COVID- 19 have been suggested, such as beta cell function aggravation, stress hyperglycaemia and abnormal glucose metabolism. SARS CoV-2 infection may precipitate diabetic ketoacidosis (DKA), a severe complication of diabetes [8].

A study from England highlighted a 6% rise in DKA admissions during the pandemic compared to the period before it, but only 12% of those admitted had a confirmed COVID-19 diagnosis. Furthermore, the study found that 41% of those with pre-existing type 2 diabetes mellitus experienced DKA, while 57% of the patients presenting with DKA were diagnosed with new-onset diabetes [9]. South African emergency departments have seen many patients presenting with COVID-19 and related complications [2]. In a case series from Durban, South Africa, there was an increased number of patients presenting with diabetic ketoacidosis (DKA) than pre-pandemic. There was also an increased mortality rate in comorbid DKA and COVID-19 [10]. In developed countries, the pre-pandemic mortality rate of DKA was under 1%, whereas in South Africa, it ranged from 6.8% to 9% [11].

Looking at clinical characteristics, a systematic review published in 2020 noted that the majority of patients with both DKA and COVID-19 had a prior diagnosis of Type 2 Diabetes Mellitus (DM) [12]. A study conducted in New York City investigated the clinical characteristics of individuals with diabetic ketoacidosis (DKA), making comparisons between those who were positive and negative for COVID-19. The results indicated a correlation

between older age and the presence of COVID-19 in DKA patients, with older patients having a higher mortality rate of 57% compared to those without the virus. [8] In another single-centre study from the USA, 43 patients diagnosed with both COVID-19 and DKA were evaluated, revealing a median age of 52 years and glycated haemoglobin levels of 8% or higher, which corresponded to a mortality rate of 58% [13]. Additionally, a case series from South Africa looked at ten patients with DKA and COVID-19, most of whom were younger than 45 years, had an average hospital length of stay of 3.3 days, and a mortality rate of 30% [10]

To date, there are few studies with small sample sizes describing the relationship between COVID-19 and DKA, therefore there is little consensus on the clinical effect that COVID-19 has on DKA. The objective of this research was to characterise the clinical features and burden of disease in patients diagnosed with SARS CoV-2 infection and DKA in a regional hospital located in Johannesburg, South Africa.

Methods

Study design

This was a single centre, retrospective observational study. All patients aged 12 years and older (institution based cut off for paediatrics), who presented to Tambo Memorial Hospital (TMH) Emergency Department between the period of 1 April 2020 to 31 August 2021 were included. Patients diagnosed with DKA were identified from the (ED) registers. At time of presentation, patients were tested for COVID-19 by nasopharyngeal reverse transcriptase polymerase chain reaction assay (RT-PCR).

Setting

TMH is in the Ekurhuleni region of Johannesburg and manages approximately 200 patients annually in Diabetic Ketoacidosis (DKA) or Hyperosmolar Hyperglycemic State (HHS). During the COVID-19 pandemic, the hospital converted sections into an Intensive Care Unit (ICU) and High Care Unit (HCU) to accommodate the increased burden of disease. The study period of 1 year and 4 months spans the three periods of peak COVID-19 infection (or three waves) in South Africa. Diagnosis of DKA was made according to the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) criteria: glucose $>13.9\text{mmol/L}$; acidosis $\text{pH}<7.3$ or $\text{HCO}_3^- <18\text{mmol/L}$ and ketonuria). [14] All files that had sufficient data to meet the primary objectives were included the study. Differentiation

between type 1 DM and type 2 DM was based on the clinical records, as the patients were already known to the hospital's medical outpatient department.

Data Collection

Emergency Department registers from 1 April 2020 to 31 August 2021 were reviewed by the primary researcher for patients with DKA.

During the study period, 236 patients were treated for DKA as per hospital registers. A total of 105 files were retrieved by hospital clerks using a convenience sampling method over a 5 month period. It was noted that 30 COVID-19 patients were sufficient as per the central limit theorem and therefore data collection was completed. One file was excluded because ED notes were missing. Patient clinical records were analysed and data captured on an excel spreadsheet which was designed with all required parameters. Patients identified were allocated a participant identification number and no identifying characteristics were saved on the data capture form. Only the primary researcher had access to the password protected participant linkage form with the corresponding hospital and study number. Only files were included that had information regarding the main objectives: demographics of patients, the burden of disease, and factors affecting severity such as blood gas values, and ketones. Files without the required information were not considered for the research.

Data analysis

The data was analysed using IBM SPSS version 28. Descriptive statistics were calculated for all variables with mean and standard deviation. Data was considered statistically significant if $p < 0.05$. The association between SARS CoV-2 and DKA, patient demographics, comorbidities, and other clinical factors were assessed using the Mann Whitney U and the Kruskal-Wallis tests. Multivariate logistic regression analysis was used to predict the relationships between variables.

Ethics

Ethics approval was obtained from the University of the Witwatersrand: Human Research Ethics Committee of the Faculty of Health Sciences (Clearance certificate: MP 220477).

Permission to conduct research was also obtained from the Head of the Emergency Unit and CEO of TMH.

Results

The files of 104 patients were identified and analysed. Of these, thirty-five patients were noted to be COVID-19 positive (33.65%). The median age of the patients was 37 years. The majority of the patients were of African descent: 31 out of 35 who tested positive for COVID-19 and 54 out of 69 who tested COVID-19 negative. Irrespective of COVID-19 status there was a male predominance of 58.65%. Of note sixty-four patients (61.53%) had pre-existing DM and forty patients (38.46%) were diagnosed with Diabetes Mellitus on admission, irrespective of COVID-19 diagnosis (Table 1). Other notable comorbidities, regardless of COVID-19 diagnosis, included hypertension in thirty-seven patients (36.58%), human immunodeficiency virus (HIV) in twelve patients (11.54%), and dyslipidemia in five patients (4.81%).). The study identified patients in DKA during different infection waves as follows: in the first wave, 16 out of 45 were COVID-19 positive; in the second wave 4 out of 23 were COVID-19 positive; and in the third wave, 15 out of 36 were COVID-19 positive.

Table 1: Descriptive characteristics and clinical profile of patients in DKA

	COVID-19 positive (N=35)		COVID-19 negative (N=69)		P values
	N	%	N	%	
Age					0.28
<25	3	8.57	13	18.84	
25-34	6	17.14	20	28.99	
35-44	8	22.86	14	20.29	
45-54	7	20.00	10	14.49	
55+	11	31.43	12	17.39	
Sex					0.84
Male	20	57.14	41	59.44	
Female	15	42.86	28	40.58	

Race					0.69
Asian	0	0	2	2.90	
African	31	88.57	54	78.26	
Mixed race	1	2.86	2	2.90	
White	3	8.57	11	15.94	
Comorbidities					
Type 1 DM	5	14.29	24	34.78	0.08
Type 2 DM	15	42.85	20	28.99	
Newly diagnosed DM	15	42.85	25	36.23	
Hypertension	16	45.71	21	30.43	0.14
HIV	6	17.14	6	8.70	0.21
Dyslipidaemia	1	2.86	4	5.80	0.66
Treatment History					0.11
Insulin	5	14.29	25	36.23	
Metformin	6	17.14	4	5.80	
Defaulted Insulin/ Oral medication	2	5.71	5	7.25	
Antiretrovirals	4	11.43	2	2.90	
Antihypertensives	2	5.71	2	2.90	
Unknown treatment	4	11.43	4	5.80	
Multiple agents	4	11.43	11	15.94	
Not on medication	8	22.86	16	23.19	

Table 2: Multivariate analysis of COVID-19 positive and variables

Outcome variable	Coefficient B	P value	Odds ratio	95% Confidence Interval
Age	0.03	0.024	1.03	1.00-1.06
Na	0.06	0.045	1.06	1.00-1.12
DM Type 2	1.28	0.032	3.6	1.11-11.64

Associations between COVID-19, age and comorbidities

Multivariable logistic regression analysis showed a significant difference in age between DKA patients who tested positive for COVID-19 and those who tested negative, with COVID-19 positive patients being older on average. [95% confidence interval (CI), 44.66 ± 15.18 vs. 37.36 ± 14.89 , $p = 0.02$]. Further analysis of diabetic patients who tested positive for COVID-19 revealed that 5 out of 29 patients had Type 1 diabetes mellitus (DM), while 15 out of 35 had Type 2 DM. This indicated a significantly higher prevalence of Type 2 DM compared to Type 1 DM among the patients (17.2% vs. 42.9%, $p = 0.03$). No other significant associations were found in this cohort. (Table2)

The Biochemical markers on admission were similar in both groups (COVID-19 positive and negative). The mean hemoglobin A1C (HbA1C) was 13.56 % and 13.52 %; pH: 6.95 and 6.90, osmolality: 305 vs 302 and anion gap 21.72 and 22.11 respectively for COVID-19 positive and negative patients. There was no statistically significant association observed between these parameters (Table 3).

Table 3: Biochemical makers at admission

	COVID-19 positive mean (SD)	COVID-19 negative mean (SD)	P value
CRP	76.51 (94.73)	61.18 (103.98)	0.09
HbA1C (%)	13.56 (2.87)	13.52 (2.99)	0.95
WCC	12.12 (5.57)	16 (10.07)	0.08
Urea	10.37(5.72)	10.30(8.20)	0.38
Creatinine	137.86 (64.67)	153.43 (99.54)	0.51
Ph	6.95 (1.22)	6.90 (1.21)	0.15
Glucose	27.65 (9.15)	29.76 (9.61)	0.27
Osmolarity	305.96 (27.43)	302.67 (18.23)	0.60
Anion Gap	21.72 (6.27)	22.11 (6.77)	0.78

Burden of disease and mortality

The mean length of ED stay was 12.23 (+/-11.31) hours in the COVID-19 positive group and 11.84 (+/-10.31) hours COVID-19 negative group (p:0.84). The mean hospital stay was 8.26 (+/-4.18) days in the COVID-19 positive group, compared to 7.20 (+/-3.81) days in the COVID-19 negative group p=0.22 (Figure 1A & 1B).

Regarding the level of care, five patients required ICU hospitalization. Among them, only two tested positive for COVID-19—a 31-year-old and a 46-year-old—both newly diagnosed with diabetes. The COVID-19-negative ICU patients included two with Type 1 diabetes and one who was newly diagnosed. Their ages were 16, 27, and 37 years.

Regarding respiratory symptoms and treatment, of the 35 COVID-19 positive patients, only twelve needed respiratory support. The majority experienced mild symptoms, with three requiring nasal cannulas, six requiring face mask oxygen, one requiring high flow nasal cannula, and two requiring intubation. Inotropic support was started for one patient. Only one patient from the COVID-19 negative group required intubation for low GCS which subsequently improved and patient was discharged.

Among the COVID-19 positive group, one patient died (2.86%), one patient declined hospital treatment, and three patients were transferred to a quaternary facility. No deaths were noted within the COVID-19 negative group.

Fig 1A - Mean number of hours spent in ED




Fig 1B - Mean number of days spent in hospital




Figure 1: Length of stay

Discussion:

The exact pathophysiology of the interaction of DKA in COVID-19 is not fully understood, with limited information regarding clinical characteristics and burden of disease.

The bidirectional relationship between hyperglycaemia and COVID-19 has been reported in case studies. This study analysed data from patients presenting in DKA who tested positive and negative for COVID-19.

The objective was to look at clinical characteristics, burden of disease and examine the relationship between COVID-19 and hyperglycaemia, particularly within a South African context.

This study observed a predominance of males (58.65%) and individuals of African ethnicity (81.73%), likely reflecting the characteristics of the underlying population. These results were similar to a small study from Durban, South Africa with 10 patients who found a male predominance of 60% and African ethnicity of 90% [10].

A mean age of 44.7 years was noted among COVID-19 positive patients and 37.4 in the COVID-19 negative group. A statistically significant association was found between patients who tested positive for COVID-19 and were older ($p=0.02$). These findings are similar to the results of a New York study by Patel et al (mean age 58.6 and COVID-19 patients were older $p=0.01$) [8].

Our study noted that diabetic patients who tested positive for COVID-19 were significantly more likely to have type 2 DM compared to type 1 DM ($p = 0.03$) which is consistent with findings from a case series from Durban and the New York city study [8,10]. Additionally, our study identified 40 newly diagnosed diabetic patients in DKA, with 15 of them testing positive for COVID-19, accounting for 38%. This contrasts with the England study that noted 7% of patients had newly diagnosed DM with concurrent COVID-19 [9].

Regarding the disease burden, a 2023 study conducted in the United Arab Emirates analysed eleven COVID-19-positive patients with DKA. The study found that these patients had an

average HbA1C of 13.5%, which closely matches the HbA1C of 13.56% in our study. HbA1C is used as a marker of treatment compliance in patients with Diabetes Mellitus. The UAE study reported an average CRP of 50, whereas our study found an average CRP of 76. Additionally, the pH average was 7.2 in their study, compared to 6.9 in ours [15]. The Durban study reported an average pH of 7.02, CRP of 193, HbA1C of 11.9 and an average hospital stay of 3.3 days, whereas our study found a longer average stay of 7.56 days. These differences may indicate an increased severity among our cohort of patients as compared to the UAE and Durban study. [10;15]

The mortality rate among patients with DKA and COVID-19 in our study was notably lower at 2.86%, compared to higher rates reported in case studies and a systematic review by Pal et al., where patients with COVID-19 frequently presented with more severe DKA, and mortality rates ranged from 18% to 58% [9,12, 13, 15]. The systematic review of patients with DKA and COVID-19 had a mortality rate of 45% and noted that a low pH on presentation had a significant association with in-hospital mortality [12]. The Durban study noted a 30% mortality among patients with concurrent DKA and COVID-19 diagnosis, but this could be attributed to the small study size [10]. The New York study assessed baseline characteristics of 35 patients with DKA and COVID-19 and noted a 57% mortality, higher than reported elsewhere. Additionally, the mean age of patients in the New York study was older compared to ours, with an average age of 58.6 years versus 44.7 years, respectively [8].

The low mortality rate noted in this study could be attributed to the time periods investigated and the sample size. In South Africa, the COVID-19 waves were driven by the spread of a new, more transmissible COVID-19 variant. The first wave spanned June 2020 to August 2020; the second wave from November 2020 to February 2021, and the third wave from May 2021 to August 2021[16]. Regarding the COVID-19 waves documented, we noted the following: during the first wave 16/45 patients tested COVID-19 positive; 4/23 during the second wave and 15/36 during the third wave. This differs from another retrospective South African study, Bhikoo R et al, that noted an increased rate of infection and hospitalisation in the second and third waves [17].

Early during the pandemic, COVID-19 treatment options were based on case discussions and expert opinion with varying treatment strategies suggested [18]. It could be hypothesized that the longer time frame of our study, ongoing vaccination efforts that had been implemented,

increase in healthcare system capacity and improved COVID-19 treatment protocols, could have contributed to a decrease in the mortality rate [19].

Limitations

This study has several limitations that must be considered. The sample size was small, with only thirty-five COVID-19 positive patients out of 104, which limits statistical power and generalizability to larger populations. Additionally, the use of convenience sampling from a single regional hospital may introduce selection bias, reducing the representativeness of the cohort. The disproportionate number of Type 1 diabetes (DMT1) patients compared to Type 2 diabetes (DMT2) may also skew the results, as clinical features and outcomes could differ between these groups. Incomplete or unavailable data further introduced potential biases, limiting the depth of the analysis. Finally, challenges in accessing patient records due to the public healthcare setting affected sample completeness and data quality.

Conclusion

Based on our study, the demographics of patients who tested COVID-19 positive and negative with DKA were similar to other studies. We found a significant correlation between COVID-19-positive patients and those with Diabetes Mellitus Type 2 and older age.. Patients with DKA and COVID-19 had a lower mortality rate of 2.86% than other studies of similar size which could be due to vaccination efforts as well as improved COVID-19 treatment protocols.

Dissemination of results

The study results will be shared to participating institutions and disseminated through various emergency medicine social media platforms.

Author contributions

HD, PM, and RK were involved in the conception of the work, data analysis and interpretation, and critically revised the manuscript for important intellectual content. Their contributions are as follows: HD 60%, PM 30%, and RK 10%. All authors approved the final version to be published and are accountable for all aspects of the work.

Conflict of interest

The authors confirm that they have no conflicts of interest to disclose.

References

1. World Health Organization. Coronavirus disease (COVID-19) pandemic [Internet]. World Health Organization. 2023. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
2. SA coronavirus COVID-19 daily updates & cases available: <https://sacoronavirus.co.za/covid-> accessed 11 August 2024
3. Bornstein SR, Zimmet P, Rubino F, Ludwig B. Management of Diabetes in patients with COVID-19 – Authors’ reply. *The Lancet Diabetes & Endocrinology*. 2020 Aug;8(8):669–70.
4. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. *J Clin Virol*. 2020 Jun;127:104354. doi: 10.1016/j.jcv.2020.104354. Epub 2020 Apr 9. PMID: 32305882; PMCID: PMC7195018.
5. Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. *Nutrition & Diabetes* [Internet]. 2021 Jun 23 [cited 2021 Sep 8];11(1):1–5. Available from: <https://www.nature.com/articles/s41387-021-00163-2>
6. Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in COVID- 19. *N Engl J Med*. 2020. doi:10.1056/nejmc2018688.
7. Kazakou P, Lambadiari V, Ikonomidis I, Kountouri A, Panagopoulos G, Athanasopoulos S, Korompoki E, Kalomenidis I, Dimopoulos MA, Mitrakou A. Diabetes and COVID-19; A Bidirectional Interplay. *Front Endocrinol (Lausanne)*. 2022 Feb 17;13:780663. doi: 10.3389/fendo.2022.780663. PMID: 35250853; PMCID: PMC8891603.
8. Patel U, Deluxe L, Salama C, Jimenez AR, Whiting A, Lubin C, et al. Evaluation of Characteristics and Outcomes for Patients with Diabetic Ketoacidosis (DKA) With and Without COVID-19 in Elmhurst Queens During Similar Three-Month Periods in 2019 and 2020. *Cureus*. 2021 Jul 16;
9. Misra S, Barron E, Vamos E, et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. *Lancet Diabetes Endocrinol* 2021; published online Sept 2. [https://doi.org/10.1016/S2213-8587\(21\)00208-4](https://doi.org/10.1016/S2213-8587(21)00208-4).

10. Dick HN, Naidoo K. COVID-19 and diabetic ketoacidosis: A case series at an urban district hospital in South Africa. *South African Family Practice*. 2022 Sep 22;64(1).
11. Jivan D. Management of diabetic ketoacidosis. *JEMDSA*. 2011; 16 (1):10-14
12. Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature. *Diabetes & Metabolic Syndrome* [Internet]. 2020 [cited 2020 Dec 13];14(6):1563–9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434433/>
13. Singh B, Kaur P, Patel P, Reid RJ, Kumar A, Kaur S, et al. COVID-19 and Diabetic Ketoacidosis: A Single Center Experience. *Cureus*. 2021 Jan 30;
14. The 2017 SEMDSA Guidelines for the Management of Type 2 Diabetes | Journal of Endocrinology, Metabolism and Diabetes of South Africa. www.jemdsacoza [Internet]. [cited 2021 Sep 15]; Available from: <http://www.jemdsa.co.za/index.php/JEMDSA/article/view/647>
15. Hana AL Sughaiyer, Abeer AL Haj, Samia Murad Ibrahim Abdulrahman; Diabetic Ketoacidosis in COVID-19 Patients: Clinical Characteristics and Outcomes – A Retrospective Study in a Single Tertiary Care Hospital, Dubai, United Arab Emirates. *Dubai Diabetes Endocrinol J* 2 October 2023; 29 (2): 107–115. <https://doi.org/10.1159/000531683>
16. Jassat W, Abdool Karim SS, Mudara C, Welch R, Ozougwu L, Groome MJ, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. *The Lancet Global Health*. 2022 Jul;10(7):e961–9.
17. Bhikoo, R. et al. (2022) ‘COVID-19 and hyperglycaemic emergencies: perspectives from a developing country’, *Journal of Endocrinology, Metabolism and Diabetes of South Africa*, 27(1), pp. 42–48. doi: 10.1080/16089677.2021.1939934
18. McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. *Open Forum Infect Dis*. 2020 Mar 23;7(4):ofaa105. doi: 10.1093/ofid/ofaa105. PMID: 32284951; PMCID: PMC7144823.
19. Crichton ML, Goeminne PC, Tuand K, Vandendriessche T, Tonia T, Roche N, Chalmers JD; European Respiratory Society COVID-19 Task Force. The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. *Eur Respir*

